Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if combination treatment with cemiplimab,
motixafortide, gemcitabine, and nab-paclitaxel is effective in decreasing the size of the
tumor(s), if it will prolong life in patients, and if it's safe. The treatment consists of
standard chemotherapy (gemcitabine and nab-paclitaxel) which is FDA approved and is standard
treatment for patients with pancreatic adenocarcinoma. Participants will receive
immunotherapy (cemiplimab) which activates the body's immune system to attack cancer cells.
Cemiplimab is FDA approved for treatment of skin cancer but not for pancreas cancer.
Participants will also receive Motixafortide, a new medication which has shown in the
laboratory to help immunotherapy work better. Motixafortide has been tested together with
immunotherapy (Pembrolizumab), and chemotherapy (5-Fluorouracil and liposomal Irinotecan) and
was deemed safe to test additional patients. Motixafortide has not been tested with the
specific immunotherapy (Cemiplimab) and chemotherapy (gemcitabine and nab-paclitaxel) which
participants will receive and is being tested in this clinical trial.